Search

Your search keyword '"Schlembach, Pamela J"' showing total 28 results
Start Over Author "Schlembach, Pamela J"
28 results on '"Schlembach, Pamela J"'

1. Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer

Author

Jacomina, Luisa E., Swanson, David M., Mitchell, Melissa P., Woodward, Wendy A., Smith, Benjamin D., Hoffman, Karen E., Goodman, Chelain R., Garber, Haven R, Sun, Susie X., Yap, Timothy A., Meric-Bernstam, Funda, Arzu, Isidora Y., Bloom, Elizabeth S., Schlembach, Pamela J., Strom, Eric A., Stauder, Michael C., and Shaitelman, Simona F.

Published
2024
Full Text
View/download PDF

2. Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation With Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy

Author

Stecklein, Shane R., Shaitelman, Simona F., Babiera, Gildy V., Bedrosian, Isabelle, Black, Dalliah M., Ballo, Matthew T., Arzu, Isadora, Strom, Eric A., Reed, Valerie K., Dvorak, Tomas, Smith, Benjamin D., Woodward, Wendy A., Hoffman, Karen E., Schlembach, Pamela J., Kirsner, Steve M., Nelson, Christopher L., Yang, Jinzhong, Guerra, William, Dibaj, Shiva, and Bloom, Elizabeth S.

Published
2019
Full Text
View/download PDF

3. A phase II clinical trial of frameless fractionated stereotactic radiotherapy for brain metastases

Author

Garg, Amit K, primary, Hernandez, Mike, additional, Schlembach, Pamela J, additional, Bowers, John R, additional, McAleer, Mary F, additional, Brown, Paul D, additional, Gopal, Ramesh, additional, Wiederhold, Lee, additional, Swanson, Todd, additional, Shah, Shalin J, additional, Li, Jing, additional, Ferguson, Sherise D, additional, Philip, Nancy V, additional, DeGracia, Lilybeth, additional, Bloom, Elizabeth S, additional, and Chun, Stephen G, additional

Published
2023
Full Text
View/download PDF

6. Optimizing Preventive Adjuvant Linac-Based (OPAL) Radiation: A Phase 2 Trial of Daily Partial Breast Irradiation

Author

Reddy, Jay P., primary, Lei, Xiudong, additional, Bloom, Elizabeth S., additional, Reed, Valerie K., additional, Schlembach, Pamela J., additional, Arzu, Isidora, additional, Mayo, Lauren, additional, Chun, Stephen G., additional, Ahmad, Neelofur R., additional, Stauder, Michael C., additional, Gopal, Ramesh, additional, Kaiser, Kels, additional, Fang, Penny, additional, and Smith, Benjamin D., additional

Published
2023
Full Text
View/download PDF

8. A phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastases.

Author

Garg, Amit K, Hernandez, Mike, Schlembach, Pamela J, Bowers, John R, McAleer, Mary F, Brown, Paul D, Gopal, Ramesh, Wiederhold, Lee, Swanson, Todd, Shah, Shalin J, Li, Jing, Ferguson, Sherise D, Philip, Nancy V, DeGracia, Lilybeth, Bloom, Elizabeth S, and Chun, Stephen G

Subjects
STEREOTACTIC radiotherapy, BRAIN metastasis, TREATMENT of brain cancer
Abstract

Stereotactic radiation therapy yields high rates of local control for brain metastases, but patients in rural or suburban areas face geographic and socioeconomic barriers to its access. We conducted a phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastases in an integrated academic satellite network for patients 18 years of age or older with 4 or fewer brain metastases. Dose was based on gross tumor volume: less than 3.0 cm, 27 Gy in 3 fractions and 3.0 to 3.9 cm, 30 Gy in 5 fractions. Median follow-up was 10 months for 73 evaluable patients, with a median age of 68 years. Median intracranial progression-free survival was 7.1 months (95% confidence interval = 5.3 to not reached), and median survival was 7.2 months (95% confidence interval = 5.4 to not reached); there were no serious adverse events. Outcomes of this trial compare favorably with contemporary trials, and this treatment strategy provides opportunities to expand stereotactic radiation therapy access to underserved populations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

10. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial

Author

Shaitelman, Simona F., Schlembach, Pamela J., Arzu, Isidora, Ballo, Matthew, Bloom, Elizabeth S., Buchholz, Daniel, Chronowski, Gregory M., Dvorak, Tomas, Grade, Emily, Hoffman, Karen E., Kelly, Patrick, Ludwig, Michelle, Perkins, George H., Reed, Valerie, Shah, Shalin, Stauder, Michael C., Strom, Eric A., Tereffe, Welela, Woodward, Wendy A., Ensor, Joe, Baumann, Donald, Thompson, Alastair M., Amaya, Diana, Davis, Tanisha, Guerra, William, Hamblin, Lois, Hortobagyi, Gabriel, Hunt, Kelly K., Buchholz, Thomas A., and Smith, Benjamin D.

Published
2015
Full Text
View/download PDF

12. Enhancing clinical trial enrollment at MD Anderson Cancer Center satellite community campuses

Author

Ludmir, Ethan B., primary, Adlakha, Erica K., additional, Chun, Stephen G., additional, Reed, Valerie K., additional, Arzu, Isidora Y., additional, Ahmad, Neelofur, additional, Bloom, Elizabeth, additional, Chronowski, Gregory M., additional, Delclos, Marc E., additional, Mayo, Lauren L., additional, Schlembach, Pamela J., additional, Liao, Zhongxing, additional, Koong, Albert C., additional, Herman, Joseph M., additional, and Shah, Shalin J., additional

Published
2019
Full Text
View/download PDF

13. Association of Transforming Growth Factor β Polymorphism C−509T With Radiation-Induced Fibrosis Among Patients With Early-Stage Breast Cancer

Author

Grossberg, Aaron J., primary, Lei, Xiudong, additional, Xu, Ting, additional, Shaitelman, Simona F., additional, Hoffman, Karen E., additional, Bloom, Elizabeth S., additional, Stauder, Michael C., additional, Tereffe, Welela, additional, Schlembach, Pamela J., additional, Woodward, Wendy A., additional, Buchholz, Thomas A., additional, and Smith, Benjamin D., additional

Published
2018
Full Text
View/download PDF

14. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer

Author

Hoffman, Karen E., primary, Voong, K. Ranh, additional, Levy, Lawrence B., additional, Allen, Pamela K., additional, Choi, Seungtaek, additional, Schlembach, Pamela J., additional, Lee, Andrew K., additional, McGuire, Sean E., additional, Nguyen, Quynh, additional, Pugh, Thomas J., additional, Frank, Steven J., additional, Kudchadker, Rajat J., additional, Du, Weiliang, additional, and Kuban, Deborah A., additional

Published
2018
Full Text
View/download PDF

15. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer

Author

Hoffman, Karen E., primary, Skinner, Heath, additional, Pugh, Thomas J., additional, Voong, Khinh R., additional, Levy, Lawrence B., additional, Choi, Seungtaek, additional, Frank, Steven J., additional, Lee, Andrew K., additional, Mahmood, Usama, additional, McGuire, Sean E., additional, Schlembach, Pamela J., additional, Du, Weiliang, additional, Johnson, Jennifer, additional, Kudchadker, Rajat J., additional, and Kuban, Deborah A., additional

Published
2018
Full Text
View/download PDF

16. Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated versus Hypofractionated Whole-Breast Irradiation

Author

Swanick, Cameron W., Lei, Xiudong, Shaitelman, Simona F., Schlembach, Pamela J., Bloom, Elizabeth S., Fingeret, Michelle C., Strom, Eric A., Tereffe, Welela, Woodward, Wendy A., Stauder, Michael C., Dvorak, Tomas, Thompson, Alastair M., Buchholz, Thomas A., and Smith, Benjamin D.

Subjects
Adult, Aged, 80 and over, Humans, Breast Neoplasms, Female, Radiotherapy, Adjuvant, Dose Fractionation, Radiation, Longitudinal Studies, Patient Reported Outcome Measures, Middle Aged, Article, Aged
Abstract

The authors compared longitudinal patient-reported outcomes and physician-rated cosmesis with conventionally fractionated whole-breast irradiation (CF-WBI) versus hypofractionated whole-breast irradiation (HF-WBI) within the context of a randomized trial.From 2011 to 2014, a total of 287 women with American Joint Committee on Cancer stage 0 to stage II breast cancer were randomized to receive CF-WBI (at a dose of 50 grays in 25 fractions plus a tumor bed boost) or HF-WBI (at a dose of 42.56 grays in 16 fractions plus a tumor bed boost) after breast-conserving surgery. Patient-reported outcomes were assessed using the Breast Cancer Treatment Outcome Scale (BCTOS), the Functional Assessment of Cancer Therapy-Breast, and the Body Image Scale and were recorded at baseline and 0.5, 1, 2, and 3 years after radiotherapy. Physician-rated cosmesis was assessed at the same time points. Outcomes by treatment arm were compared at each time point using a 2-sided Student t test. Multivariable mixed effects growth curve models assessed the effects of treatment arm and time on longitudinal outcomes.Of the 287 patients enrolled, 149 were randomized to CF-WBI and 138 were randomized to HF-WBI. At 2 years, the Functional Assessment of Cancer Therapy-Breast Trial Outcome Index score was found to be modestly better in the HF-WBI arm (mean 79.6 vs 75.9 for CF-WBI; P = .02). In multivariable mixed effects models, treatment arm was not found to be associated with longitudinal outcomes after adjusting for time and baseline outcome measures (P≥.14). The linear effect of time was significant for BCTOS measures of functional status (P = .001, improved with time) and breast pain (P = .002, improved with time).In this randomized trial, longitudinal outcomes did not appear to differ by treatment arm. Patient-reported functional and pain outcomes improved over time. These findings are relevant when counseling patients regarding decisions concerning radiotherapy. Cancer 2016. © 2016 American Cancer Society. Cancer 2016;122:2886-2894. © 2016 American Cancer Society.

Published
2016

17. Longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation

Author

Swanick, Cameron W., primary, Lei, Xiudong, additional, Shaitelman, Simona F., additional, Schlembach, Pamela J., additional, Bloom, Elizabeth S., additional, Fingeret, Michelle C., additional, Strom, Eric A., additional, Tereffe, Welela, additional, Woodward, Wendy A., additional, Stauder, Michael C., additional, Dvorak, Tomas, additional, Thompson, Alastair M., additional, Buchholz, Thomas A., additional, and Smith, Benjamin D., additional

Published
2016
Full Text
View/download PDF

28. Association of Transforming Growth Factor β Polymorphism C-509T With Radiation-Induced Fibrosis Among Patients With Early-Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Author

Grossberg AJ, Lei X, Xu T, Shaitelman SF, Hoffman KE, Bloom ES, Stauder MC, Tereffe W, Schlembach PJ, Woodward WA, Buchholz TA, and Smith BD

Subjects
Adult, Aged, Aged, 80 and over, Biomarkers, Tumor genetics, Breast Neoplasms pathology, Breast Neoplasms surgery, Female, Fibrosis genetics, Fibrosis pathology, Follow-Up Studies, Genetic Predisposition to Disease, Genotype, Humans, Mastectomy, Segmental, Middle Aged, Neoplasm Staging, Radiation Injuries pathology, Radiotherapy, Adjuvant adverse effects, Retrospective Studies, Breast pathology, Breast radiation effects, Breast Neoplasms genetics, Breast Neoplasms radiotherapy, Polymorphism, Single Nucleotide, Radiation Injuries genetics, Transforming Growth Factor beta1 genetics
Abstract

Importance: Whether genetic factors can identify patients at risk for radiation-induced fibrosis remains unconfirmed., Objective: To assess the association between the C-509T variant allele in the promoter region of TGFB1 and breast fibrosis 3 years after radiotherapy., Design, Setting, and Participants: This is an a priori-specified, prospective, cohort study nested in an open-label, randomized clinical trial, which was conducted in community-based and academic cancer centers to compare hypofractionated whole-breast irradiation (WBI) (42.56 Gy in 16 fractions) with conventionally fractionated WBI (50 Gy in 25 fractions) after breast-conserving surgery. In total, 287 women 40 years or older with pathologically confirmed stage 0 to IIA breast cancer treated with breast-conserving surgery were enrolled from February 2011 to February 2014. Patients were observed for a minimum of 3 years. Outcomes were compared using the 1-sided Fisher exact test and multivariable logistic regression., Exposures: A C-to-T single-nucleotide polymorphism at position -509 relative to the first major transcription start site (C-509T) of the TGFB1 gene., Main Outcomes and Measures: The primary outcome was grade 2 or higher breast fibrosis as assessed using the Late Effects Normal Tissue/Subjective, Objective, Medical Management, Analytic scale (range, 0 to 3) three years after radiotherapy., Results: Among 287 women enrolled in the trial, TGFB1 genotype and 3-year radiotherapy-induced toxicity data were available for 174 patients, of whom 89 patients (51%) with a mean (SD) age of 60 (8) years had at least 1 copy of C-509T. Grade 2 or higher breast fibrosis was present in 12 of 87 patients with C-509T (13.8%) compared with 3 of 80 patients without the allele variant (3.8%) (absolute difference, 10.0%; 95% CI, 1.7%-18.4%; P = .02). The results of multivariable analyses indicated that only C-509T (odds ratio, 4.47; 95% CI, 1.25-15.99; P = .02) and postoperative cosmetic outcome (odds ratio, 7.09; 95% CI, 2.41-20.90; P < .001) were significantly associated with breast fibrosis risk., Conclusions and Relevance: To date, this study seems to be the first prospective validation of a genomic marker for radiation fibrosis. The C-509T allele in TGFB1 is a key determinant of breast fibrosis risk. Assessing TGFB1 genotype may facilitate a more personalized approach to locoregional treatment decisions in breast cancer., Trial Registration: ClinicalTrials.gov identifier: NCT01266642.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results